The new proprietary cell line development platform combines a robust cell line, transposon technology with high throughput clone screening and single cell imaging to deliver highly efficient protein production, with high titers, offering speed at reduced risk. SAN DIEGO, June 4, 2024…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.